

SAS:gte 12/22/04 4239-64111-05
338205.doc

10/519311
DTG9 Rec PCT/PTO 22 DEC 2004
EXPRESS MAIL LABEL NO. EV514608280US
Date of Deposit: December 22, 2004
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Martin *et al.*

Application No. Not yet assigned

Filed: Herewith

Confirmation No. Not yet assigned

For: METHOD OF TREATING AUTOIMMUNE
DISEASES WITH INTERFERON-BETA
AND IL-2R ANTAGONIST

Examiner: Not yet assigned

Art Unit: Not yet assigned

Attorney Reference No. 4239-64111-05

MAIL STOP PCT
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as Express Mail Label No. EV514608280US in an envelope addressed to: MAIL STOP PCT, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Agent
for Applicant(s)

Date Mailed December 22, 2004

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97(b)(2)

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent.

Copies of United States patents and United States published patent applications do not have to be provided to the Patent Office (37 C.F.R. 1.98(a)(2)(ii)). Copies of unpublished U.S. applications do not have to be provided, as long as the application is available on PAIR, as this requirement of 37 C.F.R. § 1.98(a)(2)(iii) has been waived by the United States Patent and Trademark Office pursuant to the Official Gazette Notice on October 19, 2004 (1287 OG 163). Applicants will provide copies of such patents or applications upon request.

10/519311

SAS:gte 12/22/04 4239-64111-05
338205.doc

EXPRESS MAIL LABEL NO. EV514608280US
Date of Deposit: December 22, 2004
PATENT


Applicants filed this Information Disclosure Statement ("IDS") within three months of the date of entry of the national stage as set forth in § 1.491 in an international application. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this IDS, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550. A **duplicate** copy of the transmittal letter for this IDS is enclosed.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN LLP

By


Susan Alpert Siegel, Ph.D.
Registration No. 43,121

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446

SAS:gte 12/22/04 4239-64111-05 33816

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	4239-64111-05
Application Number	Not yet assigned
Filed	10/519311
First Named Inventor	Martin
Art Unit	Not yet assigned
Examiner Name	Not yet assigned

U.S. PATENT DOCUMENTS

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
		5,530,101	25 June 1996	Queen <i>et al.</i>
		6,096,728	01 Aug 2000	Collins <i>et al.</i>

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
		WIPO/PCT	93/01289	21 Jan 1993	Crowe <i>et al.</i>
		WIPO/PCT	00/25816	11 May 2000	Pinna <i>et al.</i>
		WIPO/PCT	2004/003156	08 Jan 2004	Leonard <i>et al.</i>

OTHER DOCUMENTS

Examiner's Initials*	Cite No. (optional)	
		BELLAMY <i>et al.</i> , "The Distribution of Interleukin-2 Receptor Bearing Lymphocytes in Multiple Sclerosis: Evidence for a Key Role of Activated Lymphocytes," <i>Clin. Exp. Immunol.</i> , 61:248-256 (1985)
		GIORELLI <i>et al.</i> , "IFN-beta1a Modulates the Expression of CTLA-4 and CD28 Splices in Human Mononuclear Cells: Induction of Soluble Isoforms," <i>J. Interferon Cytokine Res.</i> , 21:809-12 (2001)
		"Industry News (Transplantation): FDA Approval of Zenapax for Kidney Transplants Announced," <i>Cancer Weekly</i> , p.2 (1997)

EXAMINER
SIGNATURE:

DATE
CONSIDERED:

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number **107519311**
 Application Number Not yet assigned
 Filed Herewith
 First Named Inventor Martin
 Art Unit Not yet assigned
 Examiner Name Not yet assigned

JUNGHANS *et al.*, "Anti-Tac-H, a Humanized Antibody to the Interleukin 2 Receptor with New Features for Immunotherapy in Malignant and Immune Disorders," *Cancer Res.*, 50:1495-1502 (1990), abstract only.

KHOURY *et al.*, "Changes in Activated T Cells in the Blood Correlate with Disease Activity in Multiple Sclerosis," *Arch Neurol*, 57:1183-1189 (2000)

LEHKY *et al.*, "Reduction in HTLV-I Proviral Load and Spontaneous Lymphoproliferation in HTLV-I-Associated Myelopathy/Tropical Spastic Paraparesis Patients Treated with Humanized Anti-Tac," *Ann. Neurol.*, 44:942-947 (1998)

MARWICK, "Scientists Recall Progress and Promise of Translational Research," *J. Natl. Cancer Inst.*, 93:13-15 (2001)

NUSSENBLATT *et al.*, "Treatment of Noninfectious Intermediate and Posterior Uveitis with the Humanized Anti-Tac mAb: A Phase I/II Clinical Trial," *Proc. Natl. Acad. Sci.*, 96:7462-7466 (1999)

PATY *et al.*, "Interferon beta-1b is effective in relapsing -remitting multiple sclerosis," *Neurology* 43:662-667, 1993

POSEY *et al.*, "New Drugs for 1997,"
www.ascp.com/public/pubs/tcp/1997/apr/newdrugs, 21pp. (1997)

"Study of Zenapax in the Treatment of Multiple Sclerosis," www.multiple-sclerosis.org/news/Nov2000/ZenapaxMS, 4pp. (November 2000)

WANDINGER *et al.*, "Complex Immunomodulatory Effects of Interferon-beta in Multiple Sclerosis Include the Upregulation of T Helper 1-associated Marker Genes," *Ann. Neurol.*, 50(3):349-57 (2001)

EXAMINER
SIGNATURE:

DATE
CONSIDERED:

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.